



Red Chip Analyst Report

20 August 2015, Melbourne, Australia: Immuron Limited (ASX:IMC) wishes to confirm its previous announcement to the ASX, on Wednesday 19th August 2015, regarding a US Investor Roadshow where the Company is showcasing its technology platform and profile to US investment groups.

As part of this Roadshow, Immuron engaged Red Chip Companies Inc. (Red Chip) for the provision of certain US Investor Relations Services. Red Chip has today released an Analyst Report to the market in relation to the Company's current activities and future development plans. This Analyst Report has attracted significant online attention and market discussion.

The Board continues its commitment to explore strategies to enhance shareholder value, including securing investment from a wider shareholder base via alternative overseas capital markets. Any material developments regarding this will be the subject of future announcements.

A copy of the Red Chip Analyst Report will be available on the Immuron Company website at: www.immuron.com.

Contacts:

Dr Roger Aston
Non-Executive Chairman
+61 (0)3 9824 5254

ABOUT IMMURON

Immuron Ltd (ASX:IMC) is a Microbiom company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The company currently markets Travelan[®] for the prevention of travellers' diarrhoea, its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH, and it has a preclinical immunotherapy pipeline targeting immune-related diseases with unmet needs.

Immuron's main scientific alliances are with Hadassah Medical Center (Israel), Monash University (Australia) and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) (Australia).